Applications to the FY22 JWMRP MMRDA are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by 10 USC 2358. The execution management agent for this BAA is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).
This MMRDA mechanism is intended to support a logical continuation of previously funded, prior year research or development efforts relevant to the above FY22 JWMRP Focus Areas with the highest potential to augment and accelerate medical product development and healthcare solutions for military Service Members, Veterans, their families, other MHS beneficiaries, and/or the American public. The USAMRDC will implement this research program through the awarding of assistance agreements (grants and cooperative agreements), research contracts, or Other Transaction Agreements (OTAs). All invited applicants must submit full applications in accordance with the procedures outlined in this funding opportunity announcement. Collaboration with DOD organizations is encouraged when this alliance would contribute to the success of the research effort, and any funds designated for DOD laboratories or activities should be identified in the application through submission of a “Suggested Collaborating DOD Military Facility Budget Format,” Attachment 15.
Funding from this award mechanism may be used for a wide range of research projects spanning preclinical studies, translational and technology development, clinical studies (including correlative studies and initial safety and efficacy testing of promising drug and vaccine candidates, medical devices and technologies), and phase 1, phase 2, or phase 3 clinical trials.
Deadlines:
• Pre-Application Deadline: May 16, 2022
• Invitation to Submit an Application: June 2022
• Application Submission Deadline: July 28, 2022
The JWMRP Programmatic Panel identified the following Focus Areas as the highest priorities for FY22 JWMRP funding to meet critical research and development gaps and Service medical requirements. To be considered for funding, applications to the FY22 JWMRP must address at least one of the Focus Areas listed under the categories below.
Endemic and Emerging Disease Threats
Operational Medicine and Readiness
Environmental Medicine
Combat Casualty Care
Independent investigators at all academic levels (or equivalent) are eligible to be named by the organization as the PI in the application. There are no limitations on the number of applications for which an investigator may be named as a PI. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.
The anticipated total costs budgeted for the entire period of performance for a FY22 JWMRP MMRDA will not exceed $4.5M. Refer to Section II.D.6, Funding Restrictions, for detailed funding information.
